Development of Novel Patient-Reported Outcome (PRO) and Observer-Reported Outcome (ObsRO) Instruments in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA): ViSIO-PRO and ViSIO-ObsRO.

Autor: Audo I; Sorbonne Université, INSERM, CNRS, Institut de La Vision, CHNO Des Quinze-Vingts, National Rare Disease Center REFERET and INSERM-DGOS CIC 1423, 75012, Paris, France., Patalano F; Novartis Pharma AG, Basel, Switzerland., Naujoks C; Novartis Pharma AG, Basel, Switzerland., Spera C; Novartis Pharma AG, Basel, Switzerland., Fischer MD; Department of Clinical Neurosciences, University of Oxford, Oxford, UK.; Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany., Green J; Discipline of Genetics, Faculty of Medicine, Memorial University of Newfoundland, Craig L Dobbin Genetics Research Centre, St. John's, Canada., Kay C; Vitreoretinal Associates, Gainesville, FL, USA., Durham T; Foundation Fighting Blindness, Columbia, MD, USA., Williamson N; Adelphi Values Ltd, Bollington, Cheshire, UK., Bradley H; Adelphi Values Ltd, Bollington, Cheshire, UK. helena.bradley@adelphivalues.com., Barclay M; Adelphi Values Ltd, Bollington, Cheshire, UK., Boparai K; Adelphi Values Ltd, Bollington, Cheshire, UK., Banhazi J; Novartis Pharma AG, Basel, Switzerland.
Jazyk: angličtina
Zdroj: Ophthalmology and therapy [Ophthalmol Ther] 2023 Aug; Vol. 12 (4), pp. 2069-2085. Date of Electronic Publication: 2023 May 21.
DOI: 10.1007/s40123-023-00724-x
Abstrakt: Introduction: Retinitis pigmentosa (RP) and Leber congenital amaurosis (LCA) are rare inherited retinal degenerative disorders resulting in visual impairments and impacts on patients' vision-dependent activities of daily living (ADL), mobility and distal health-related quality of life (HRQoL). This study aimed to conduct qualitative research to understand the patient experience of RP/LCA across genotypes and inform development of patient- and observer-reported outcome (PRO/ObsRO) instruments in RP/LCA.
Methods: Research activities included a qualitative literature review and review of existing visual function PRO instruments in RLBP1 RP, and concept elicitation (CE) and cognitive debriefing (CD) interviews of existing PRO instruments with patients with RLBP1 RP, expert clinicians, and payers. In wider RP/LCA, a social media listening (SML) study and a qualitative literature review was conducted, while psychometric evaluation of a PRO instrument in LCA was performed. Input from expert clinicians was sought at key stages.
Results: Findings from the qualitative literature reviews identified a range of visual function symptoms which had significant impacts on patients' vision-related ADL and distal HRQoL. Patient interviews identified additional visual function symptoms and impacts not previously reported in published literature. These sources informed development and refinement of a conceptual model displaying the patient experience of RP/LCA. Review of existing visual function PRO instruments, and CD interviews evaluating their content validity, confirmed that no existing instrument provides a comprehensive assessment of all concepts relevant to patients with RP/LCA. This highlighted the need for development of the Visual Symptom and Impact Outcomes PRO and ObsRO instruments to adequately assess the patient experience of RP/LCA.
Conclusions: Results informed and supported development of the instruments to assess visual functioning symptoms and vision-dependent ADL, mobility and distal HRQoL in RP/LCA, in accordance with regulatory standards. Next steps to further support use in RP/LCA clinical trials/practice includes content and psychometric validation of the instruments in this population.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje